The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First Dosing In TP-05 Lyme Trial

• Tarsus Pharmaceuticals has already dosed the first participant in its Phase 2 Calliope trial of TP-05, an oral lotilaner-based therapy being tested in about 700 at-risk adults across U.S. Lyme-endemic regions, where no FDA-approved drug prophylaxis currently exists.
• This move extends Tarsus beyond eye-care into infectious disease prevention, targeting a large U.S. population considered at moderate to high risk for Lyme disease.
• We’ll now examine how TP-05’s Phase 2 progress, as a potential first oral Lyme prophylactic, could influence Tarsus Pharmaceuticals’ investment narrative.

Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

Tarsus Pharmaceuticals Investment Narrative Recap

To own Tarsus Pharmaceuticals, you need to believe XDEMVY can keep scaling in a young treatment category while the lotilaner platform broadens into new indications. The TP-05 Calliope Phase 2 start adds a meaningful, but still early stage, diversification angle; near term, the main catalyst remains continued XDEMVY prescription growth, with the key risk that uptake or retreatment slows and exposes the company’s reliance on a single commercial asset.

The recent TP-03 approval in China, which triggered a US$15,000,000 milestone payment, is especially relevant here, as it shows how Tarsus is already extending XDEMVY beyond the U.S. market. While TP-05 is earlier in development, this international validation of lotilaner supports the broader platform story and could help fund pipeline progress, including Lyme disease prevention, that over time may lessen today’s concentrated revenue risk.

Yet in contrast, investors should be aware that if XDEMVY’s growth or market share are pressured by new competitors or changing prescribing behavior...

Read the full narrative on Tarsus Pharmaceuticals (it's free!)

Tarsus Pharmaceuticals' narrative projects $846.8 million revenue and $237.0 million earnings by 2028. This requires 42.0% yearly revenue growth and a $329.0 million earnings increase from $-92.0 million today.

Uncover how Tarsus Pharmaceuticals' forecasts yield a $87.50 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Tarsus could reach about US$1.0 billion in revenue and roughly US$500.8 million in earnings by 2028, so this new TP-05 trial milestone may either reinforce that bullish view or prompt a rethink of how much is riding on XDEMVY versus pipeline success.

Explore 4 other fair value estimates on Tarsus Pharmaceuticals - why the stock might be worth just $87.50!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Tarsus Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tarsus Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tarsus Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 26 companies in the world exploring or producing it. Find the list for free.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com